60732-17-4

Usage

Uses

Used in Organic Synthesis:
2,5-Dimethoxybenzylbromide is used as a reagent for the methylation of various functional groups, such as alcohols and amines. Its ability to selectively methylate these groups makes it a valuable component in the synthesis of complex organic molecules and pharmaceuticals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2,5-Dimethoxybenzylbromide is used as a key intermediate in the synthesis of certain drugs and drug candidates. Its versatility in organic synthesis allows for the creation of a wide range of medicinal compounds with potential therapeutic applications.
Used in Chemical Research:
2,5-Dimethoxybenzylbromide is also utilized in chemical research as a tool to study the reactivity and behavior of different functional groups under various conditions. This helps researchers to better understand the underlying mechanisms of organic reactions and to develop new synthetic methodologies.

InChI:InChI=1/C9H11BrO2/c1-11-8-3-4-9(12-2)7(5-8)6-10/h3-5H,6H2,1-2H3

Upstream product

• 33524-31-1 2,5-dimethoxybenzyl alcohol 
• 24599-58-4 2,5-dimethoxy toluene 
• 128-08-5 N-Bromosuccinimide 
• 50-00-0 formaldehyd 
• 150-78-7 1,4-dimethoxybezene 
• 558-13-4 carbon tetrabromide 
• 93-02-7 2,5-dimethoxybenzaldehyde 
• 95-71-6 2-methylbenzene-1,4-diol 

Downstream Products

• 103441-37-8 1,4-dimethoxy-2-methoxymethyl-benzene 
• 18086-24-3 2-(2,5-dimethoxyphenyl)acetonitrile 
• 20306-76-7 2,5,2',5'-tetramethoxy-bibenzyl 
• 98346-32-8 1-(2,5-dimethoxy-benzyl)-2-[1,3]dioxolan-2-yl-pyridinium; bromide 
• 139617-95-1 2-((2,5-dimethoxyphenyl)methyl)-3-methylthiolene-1,1-dione 
• 1199-08-2 ethylhydroquinone dimethyl ether 
• 80765-03-3 trans-octahydro-1α-<(2,5-dimethoxyphenyl)methyl>-1β,4aβ-dimethyl-5β-hydroxy-2(1H)-naphthalenone 
• 33524-31-1 2,5-dimethoxybenzyl alcohol 
• 33654-63-6 3-acetyl-4-(2', 5'-dimethoxyphenyl)-2-butanone 
• 137677-99-7 2,2'-(2,5,8,11-tetraoxadodecane-1,12-diyl)bis(1,4-dimethoxybenzene) 
• 171366-63-5 2,5-dimethoxybenzyl thioacetate 
• 184485-46-9 (1S,4aS)-(+)-trans-1α-[(2,5-dimethoxyphenyl)methyl]-1β,4aβ-dimethyl-5-(2-methyl-1,3-dioxolan-2-yl)-hexahydro-2,5(3H,6H)-naphthalenedione 
• 3275-95-4 2,5-dimethoxybenzylamine 
• 147217-94-5 4-[(2,5-Dimethoxy-phenyl)-hydroxy-methyl]-2,5-dimethoxy-benzaldehyde 

Relevant academic research and scientific papers

Preparation method of 2,5-dimethoxyphenylacetic acid

The invention belongs to the technical field of drug synthesis, and particularly relates to a preparation method of 2,5-dimethoxyphenylacetic acid, wherein the method comprises the following steps: A,reacting 1,4-dimethoxybenzene in a formylation system to obtain 2,5-dimethoxybenzaldehyde; B, reacting the 2,5-dimethoxybenzaldehyde obtained in the step A with a reducing agent, extracting a reaction system, then combining organic phases, drying, concentrating under reduced pressure and distilling a crude product to obtain 2,5-dimethoxybenzyl alcohol; C, reacting the 2,5-dimethoxybenzyl alcoholobtained in the step B with a bromination reagent to obtain 2-bromomethyl-1,4-dimethoxybenzene; and D, reacting the 2-bromomethyl-1,4-dimethoxybenzene obtained in the step C with magnesium or butyl lithium and carbon dioxide in a solvent to obtain the 2,5-dimethoxyphenylacetic acid. The yield and the total yield of the 2,5-dimethoxyphenylacetic acid obtained by the method disclosed by the invention are both higher than those of 2,5-dimethoxyphenylacetic acid synthesized by a Willegerdt-Kindler method.

Preparation method of 2,5-dimethoxyphenylacetic acid

The invention belongs to the technical field of drug synthesis, and particularly relates to a preparation method of 2,5-dimethoxyphenylacetic acid, wherein the preparation method comprises the following steps: A, reacting 1,4-dimethoxybenzene with formaldehyde under the action of hydrogen halide to obtain 2-halomethyl-1,4-dimethoxybenzene; B, reacting 2-halomethyl-1,4-dimethoxybenzene obtained inthe step A with a cyanation reagent, then diluting, washing, drying and concentrating under reduced pressure, and finally carrying out reduced pressure distillation to obtain 2(2,5-dimethoxyphenyl)acetonitrile; and C, hydrolyzing the 2(2,5-dimethoxyphenyl)acetonitrile obtained in the step B, cooling, extracting, merging, drying, concentrating under reduced pressure and purifying to finally obtainthe 2,5-dimethoxyphenylacetic acid. The yield and the total yield of the 2,5-dimethoxyphenylacetic acid obtained by the method disclosed by the invention are both higher than those of the 2,5-dimethoxyphenylacetic acid synthesized by a Willgerodt-Kindler method, and the yield and the total yield of the 2,5-dimethoxyphenylacetic acid are higher than those of 2,5-dimethoxyphenylacetic acid synthesized by the Willgerodt-Kindler method.

Preparation method of 2, 5-dimethoxyphenylacetic acid

The invention belongs to the technical field of drug synthesis, and particularly relates to a preparation method of 2, 5-dimethoxyphenylacetic acid, which comprises the following steps: A. Reacting 1,4-dimethoxybenzene with formaldehyde under the action of hydrogen halide, extracting by the reaction system, merging with organic phases, drying, concentrating under reduced pressure, and purifying the crude product to obtain 2-halon methyl-1, 4-dimethoxybenzene ; and B, under the protection of inert gas, putting the 2-halo methyl-1, 4-dimethoxybenzene obtained in the step A, magnesium or butyl lithium and carbon dioxide into a solvent, and then carrying out extraction and deactivation, reduced pressure distillation, extraction, organic phase combination and reduced pressure concentration toobtain the 2, 5-dimethoxyphenylacetic acid. The yield and the total yield of the 2, 5-dimethoxyphenylacetic acid obtained by the method disclosed by the invention are both higher than those of the 2,5-dimethoxyphenylacetic acid synthesized by a Willgerodt-Kindler method.

Discovery, synthesis and anti-atherosclerotic activities of a novel selective sphingomyelin synthase 2 inhibitor

The sphingomyelin synthase 2 (SMS2) is a potential target for pharmacological intervention in atherosclerosis. However, so far, few selective SMS2 inhibitors and their pharmacological activities were reported. In this study, a class of 2-benzyloxybenzamides were discovered as novel SMS2 inhibitors through scaffold hopping and structural optimization. Among them, Ly93 as one of the most potent inhibitors exhibited IC50 values of 91 nM and 133.9 μM against purified SMS2 and SMS1 respectively. The selectivity ratio of Ly93 was more than 1400-fold for purified SMS2 over SMS1. The in vitro studies indicated that Ly93 not only dose-dependently diminished apoB secretion from Huh7 cells, but also significantly reduced the SMS activity and increased cholesterol efflux from macrophages. Meanwhile, Ly93 inhibited the secretion of LPS-mediated pro-inflammatory cytokine and chemokine in macrophages. The pharmacokinetic profiles of Ly93 performed on C57BL/6J mice demonstrated that Ly93 was orally efficacious. As a potent selective SMS2 inhibitor, Ly93 significantly decreased the plasma SM levels of C57BL/6J mice. Furthermore, Ly93 was capable of dose-dependently attenuating the atherosclerotic lesions in the root and the entire aorta as well as macrophage content in lesions, in apolipoprotein E gene knockout mice treated with Ly93. In conclusion, we discovered a novel selective SMS2 inhibitor Ly93 and demonstrated its anti-atherosclerotic activities in vivo. The preliminary molecular mechanism-of-action studies revealed its function in lipid homeostasis and inflammation process, which indicated that the selective inhibition of SMS2 would be a promising treatment for atherosclerosis.

CD16A BINDING AGENTS AND USES THEREOF

Among other things, the present disclosure provides compounds, compositions thereof, and methods of using the same. In some embodiments, compounds of the present disclosure bind to Fc receptors, e.g., CD16a. In some embodiments, compounds of the present disclosure are useful for treating various conditions, disorders or diseases including cancer.

Promotion of Appel-type reactions by N-heterocyclic carbenes

N-Heterocyclic carbenes (NHCs) have been extensively used as a versatile class of catalysts and ligands in organocatalytic and organometallic chemistry. However, there are only a small number of synthetic applications where they act as reagents. Here we demonstrate that NHCs can be used as stoichiometric redox reagents for Appel-type halogenation reactions of alcohols. This new reactivity reveals a fresh and interesting aspect and enriches the chemistry of NHCs in an underexplored area. The potential of performing this chemical transformation at the catalytic level using an NHC-oxide derivative is also investigated.

3, 5-disubstituted hydantoin compound as well as preparation method and application thereof

The invention provides a 3, 5-disubstituted hydantoin compound as well as a preparation method and an application thereof. The structure of the compound is shown in formula I in the description. The application of the 3, 5-disubstituted hydantoin compound shown in the formula I or solvates, hydrates or salts of the compound in preparation of medicines for treating Alzheimer's disease, vascular dementia and other dementia diseases with memory impairment also belongs to the protection scope. Animal experiments prove that the compound has the effect of saving memory of animal models, has high safety, does not have mutagenicity, can stay in blood for several hours after oral administration and intravenous injection, and can enter the brain.

MLKL INHIBITORS

Purine derivatives that inhibit cellular necroptosis and/or human MLKL, pharmaceutical compositions thereof, and methods of treating an MLKL-mediated disorder with an effective amount of the compound or composition. Said MLKL-mediated disorder is pathology associated necroptosis, including ischemia-reperfusion damage, neurodegeneration, and inflammatory diseases such as acute pancreatitis, multiple sclerosis, inflammatory bowel disease, and allergic colitis.

1-Trifluoromethylisoquinolines from α-Benzylated Tosylmethyl Isocyanide Derivatives in a Modular Approach

The preparation of various 1-trifluoromethylisoquinolines from α-benzylated tosylmethyl isocyanide derivatives and the commercial Togni reagent using a radical cascade is reported. The starting isocyanides are readily prepared in a modular sequence from commercial tosylmethyl isocyanide via sequential double α-alkylation, and the radical reaction proceeds under mild conditions with high efficiency without any transition-metal catalyst via electron catalysis. This valuable protocol has been successfully applied to the total synthesis of CF3-mansouramycin B.

4-oxo-alkylated tetramic acid compounds and preparation method thereof

The invention relates to novel compounds and a preparation method thereof. The general structural formula is shown as formula I in the description. Animal experiments prove that the compounds have the effect of saving memories of animal models, are high in safety, have no mutagenicity, can remain in blood for hours after oral administration and intravenous injection, can enter brains and can be used for preparing drugs for treating diseases such as Alzihemer's disease, Parkinson's disease, Huntington's disease, vascular dementia, schizophrenia, autism and the like.